WPI 2287 (Propafenone Hydrochloride Extended-Release 425 mg)
Pill with imprint WPI 2287 is White, Capsule-shape and has been identified as Propafenone hydrochloride extended-release 425 mg. It is supplied by Actavis Pharma, Inc..
Propafenone is used in the treatment of atrial fibrillation; ventricular tachycardia; atrial flutter; wolff-parkinson-white syndrome and belongs to the drug class group I antiarrhythmics. Risk cannot be ruled out during pregnancy. Propafenone 425 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for WPI 2287
Propafenone hydrochloride extended-release
- Imprint:
- WPI 2287
- Strength:
- 425 mg
- Color:
- White
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- Group I antiarrhythmics
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Labeler / Supplier:
- Actavis Pharma, Inc.
- National Drug Code (NDC):
- 00591-2287
More about propafenone
- Propafenone Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 49 Reviews – Add your own review/rating
- Drug class: group I antiarrhythmics
Consumer resources
- Propafenone
- Propafenone Tablets
- Propafenone Sustained-Release Capsules
- Propafenone (Advanced Reading)
Other brands: Rythmol, Rythmol SR
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2018 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
